Albireo, Mirum Pharmaceuticals, and Ipsen are developing IBAT inhibitor therapies targeting conditions like MASH.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Albireo, Mirum Pharmaceuticals, and Ipsen are developing IBAT inhibitor therapies targeting conditions like MASH.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Albireo
pharmaceutical company in Gothenburg Sweden
Nothing else this week.
-
Mirum Pharmaceuticals
biopharmaceutical company
-
Ipsen
company in Barcelona, Spain
Nothing else this week.
Coverage
Newest first; wire copies grouped- PR NewswireIBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight The market for IBAT inhibi